<DOC>
	<DOCNO>NCT00704158</DOCNO>
	<brief_summary>This study evaluate safety tolerability CR011-vcMMAE patient locally advance metastatic breast cancer . CR011-vcMMAE administer intravenously ( IV ) every 3 week ( q3w ) cohorts 3-6 patient confirm maximum tolerate dose ( MTD ) breast cancer patient . Once MTD confirm , 25 patient locally advance metastatic breast cancer enrol Phase II portion trial evaluate safety efficacy CR011-vcMMAE .</brief_summary>
	<brief_title>Study CR011-vcMMAE Treat Locally Advanced Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Main Females confirm breast cancer Age â‰¥ 18 year Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 2 Locally advanced metastatic disease receive least two prior chemotherapeutic regimen breast cancer , follow : At least one regimen must locally advance metastatic disease Subject must receive anthracycline , taxane , capecitabine combination unless subject intolerant candidate agent Hormonal therapy , biologic therapy ( trastuzumab bevacizumab ) , immunotherapy count one 2 regimen Subjects HER2/neu overexpressing tumor must treat trastuzumab except situation subject intolerant candidate trastuzumab Documented progressive disease within 6 month last regimen Adequate bone marrow , renal liver function Signed informed consent Main Chemotherapy , radiation , hormonal therapy , bevacizumab within two week , trastuzumab investigational therapy within three week treatment start Neuropathy &gt; NCICTCAE Grade 1 Active brain metastasis . New York Heart Association class III IV heart disease Unstable angina Uncontrolled arrhythmia A marked baseline prolongation QT/QTc interval Pregnant breastfeeding woman , woman childbearing age potential willing use effective contraception</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>CR011-vcMMAE</keyword>
	<keyword>locally advanced breast cancer</keyword>
	<keyword>metastatic breast cancer</keyword>
	<keyword>breast cancer</keyword>
	<keyword>CuraGen</keyword>
</DOC>